Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management

Faecal microflora and β-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats

(2010) Andrea M Stringer et al.   CANCER BIOLOGY & THERAPY

Clinical trial: prophylactic intravenous alanyl-glutamine reduces the severity of gastrointestinal toxicity induced by chemotherapy - a randomized crossover study

(2009) Y. LI et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Does Celecoxib Have a Role in the Treatment of Patients with Colorectal Cancer?

(2009) Marwan G. Fakih et al.   Clinical Colorectal Cancer

Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics

(2009) Federico Innocenti et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

(2009) Martin E Gore et al.   LANCET ONCOLOGY

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chemotherapy-induced diarrhoea

(2009) Rachel J Gibson et al.   Current Opinion in Supportive and Palliative Care

UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study

(2008) D M Kweekel et al.   BRITISH JOURNAL OF CANCER

UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma

(2008) Chun-Yu Liu et al.   CANCER

Irinotecan-induced mucositis is associated with changes in intestinal mucins

(2008) Andrea M. Stringer et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase III, Double-Blind Study of Depot Octreotide Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy: Results of North Central Cancer Treatment Group N00CA

(2008) James A. Martenson et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer

(2008) Ji-Youn Han et al.   LUNG CANCER

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activated charcoal to prevent irinotecan-induced diarrhea in children

(2008) Gallegos-Castorena Sergio et al.   PEDIATRIC BLOOD & CANCER

Gastrointestinal complications of oncologic therapy

(2008) Marta Davila et al.   Nature clinical practice. Gastroenterology & hepatology

Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer

(2008) Bruno Vincenzi et al.   Nature clinical practice. Oncology

Tyrosine kinase inhibitors and gut toxicity: a new era in supportive care

(2008) Dorothy Keefe et al.   Current Opinion in Supportive and Palliative Care